Pacific Biosciences
PACB
132 hedge funds and large institutions have $361M invested in Pacific Biosciences in 2020 Q1 according to their latest regulatory filings, with 19 funds opening new positions, 52 increasing their positions, 43 reducing their positions, and 30 closing their positions.
21% more repeat investments, than reductions
Existing positions increased: 52 | Existing positions reduced: 43
1.61% more ownership
Funds ownership: 75.28% → 76.89% (+1.6%)
8% less funds holding
Funds holding: 143 → 132 (-11)
14% less call options, than puts
Call options by funds: $989K | Put options by funds: $1.15M
37% less first-time investments, than exits
New positions opened: 19 | Existing positions closed: 30
39% less capital invested
Capital invested by funds: $592M → $361M (-$231M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KLCMU
Kite Lake Capital Management (UK)
London,
United Kingdom
|
+$22.5M |
| 2 |
Capital World Investors
Los Angeles,
California
|
+$22.3M |
| 3 |
WMSA
Weiss Multi-Strategy Advisers
New York
|
+$17M |
| 4 |
PC
Polar Capital
London,
United Kingdom
|
+$12.6M |
| 5 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$11M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AA
AQR Arbitrage
Greenwich,
Connecticut
|
-$35.7M |
| 2 |
MF
Magnetar Financial
Evanston,
Illinois
|
-$20.2M |
| 3 |
VI
Versor Investments
New York
|
-$16.2M |
| 4 |
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Toronto,
Ontario, Canada
|
-$6.76M |
| 5 |
Morgan Stanley
New York
|
-$5.94M |
PACB Hedge Fund Activity: Q1 2020 in Review
132 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in Pacific Biosciences (PACB) for Q1 2020, worth a combined $361M — down 39% from $592M a quarter earlier.
Sellers outnumbered buyers: 30 funds closed out of PACB and 19 opened new positions — a net loss of 11 holders — while 43 trimmed existing stakes and 52 added.
The largest buyer was Kite Lake Capital Management (UK), opening a new position worth an estimated $22.5M. The largest seller was AQR Arbitrage, exiting entirely with an estimated $35.7M sold.
- 132 institutional investors held Pacific Biosciences (PACB) as of Q1 2020, down from 143 in Q4 2019.
- Funds reported $361M of Pacific Biosciences stock for Q1 2020, down 39% quarter-over-quarter.
- 19 funds opened new Pacific Biosciences positions in Q1 2020 and 30 closed out, a net change of -11 holders.
- The largest Pacific Biosciences buyer in Q1 2020 was Kite Lake Capital Management (UK), an estimated $22.5M added.
- The largest Pacific Biosciences seller in Q1 2020 was AQR Arbitrage, an estimated $35.7M sold.
Based on aggregated 13F filings for Q1 2020.